Tags

Type your tag names separated by a space and hit enter

Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment.
Am J Respir Crit Care Med. 1995 Oct; 152(4 Pt 1):1170-4.AJ

Abstract

Regular beta 2-adrenoceptor agonist therapy may lead to a rebound increase in bronchial responsiveness on discontinuation of therapy and a reduction in bronchoprotective effects. Formoterol, a long-acting beta 2-agonist, is effective in single doses in the prevention of methacholine-induced bronchoconstriction. In a double-blind, placebo-controlled cross-over study, we examined the effect of an inhaled long-acting beta 2-adrenoceptor agonist, formoterol (24 micrograms twice a day) for 2 wk on airway function and responsiveness in 17 subjects with mild asthma (mean age, 26.3 +/- 1.4 yr) who were not taking inhaled glucocorticosteroids. FEV1 and the provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) were measured at 36, 60, and 108 h and at 2 wk after the last dose of regular treatment. In addition, PC20 was measured 12 h after the first and the last dose of formoterol and placebo. PC20 values at 36, 60, and 108 h and at 2 wk after formoterol treatment cessation were not significantly different from those after placebo. Mean FEV1 was 3.44 +/- 0.18 L after placebo compared with 3.79 +/- 0.20 L after formoterol (p < 0.001) 12 h after the first dose, and mean PC20 was 0.53 (GSEM 1.4) mg/ml after placebo compared with 2.0 (GSEM 1.4) mg/ml after formoterol (p < 0.001). After 2 wk of regular treatment, mean FEV1 at 12 h after the final dose of formoterol fell to 3.51 +/- 0.23 L compared with 3.41 +/- 0.18 L after the final dose of placebo (p = 0.03).(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Department of Thoracic Medicine, National Heart & Lung Institute, London, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

7551366

Citation

Yates, D H., et al. "Regular Formoterol Treatment in Mild Asthma. Effect On Bronchial Responsiveness During and After Treatment." American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 4 Pt 1, 1995, pp. 1170-4.
Yates DH, Sussman HS, Shaw MJ, et al. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med. 1995;152(4 Pt 1):1170-4.
Yates, D. H., Sussman, H. S., Shaw, M. J., Barnes, P. J., & Chung, K. F. (1995). Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. American Journal of Respiratory and Critical Care Medicine, 152(4 Pt 1), 1170-4.
Yates DH, et al. Regular Formoterol Treatment in Mild Asthma. Effect On Bronchial Responsiveness During and After Treatment. Am J Respir Crit Care Med. 1995;152(4 Pt 1):1170-4. PubMed PMID: 7551366.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. AU - Yates,D H, AU - Sussman,H S, AU - Shaw,M J, AU - Barnes,P J, AU - Chung,K F, PY - 1995/10/1/pubmed PY - 1995/10/1/medline PY - 1995/10/1/entrez SP - 1170 EP - 4 JF - American journal of respiratory and critical care medicine JO - Am. J. Respir. Crit. Care Med. VL - 152 IS - 4 Pt 1 N2 - Regular beta 2-adrenoceptor agonist therapy may lead to a rebound increase in bronchial responsiveness on discontinuation of therapy and a reduction in bronchoprotective effects. Formoterol, a long-acting beta 2-agonist, is effective in single doses in the prevention of methacholine-induced bronchoconstriction. In a double-blind, placebo-controlled cross-over study, we examined the effect of an inhaled long-acting beta 2-adrenoceptor agonist, formoterol (24 micrograms twice a day) for 2 wk on airway function and responsiveness in 17 subjects with mild asthma (mean age, 26.3 +/- 1.4 yr) who were not taking inhaled glucocorticosteroids. FEV1 and the provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) were measured at 36, 60, and 108 h and at 2 wk after the last dose of regular treatment. In addition, PC20 was measured 12 h after the first and the last dose of formoterol and placebo. PC20 values at 36, 60, and 108 h and at 2 wk after formoterol treatment cessation were not significantly different from those after placebo. Mean FEV1 was 3.44 +/- 0.18 L after placebo compared with 3.79 +/- 0.20 L after formoterol (p < 0.001) 12 h after the first dose, and mean PC20 was 0.53 (GSEM 1.4) mg/ml after placebo compared with 2.0 (GSEM 1.4) mg/ml after formoterol (p < 0.001). After 2 wk of regular treatment, mean FEV1 at 12 h after the final dose of formoterol fell to 3.51 +/- 0.23 L compared with 3.41 +/- 0.18 L after the final dose of placebo (p = 0.03).(ABSTRACT TRUNCATED AT 250 WORDS) SN - 1073-449X UR - https://www.unboundmedicine.com/medline/citation/7551366/Regular_formoterol_treatment_in_mild_asthma__Effect_on_bronchial_responsiveness_during_and_after_treatment_ L2 - http://www.atsjournals.org/doi/full/10.1164/ajrccm.152.4.7551366?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -